Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| EVAMED | OTHER |
Not provided
Not provided
Not provided
Not provided
Interventional, multicenter, prospective and non-comparative clinical investigation carried out in 9 French establishments in order to assess the safety of the SÉCURIDRAP® SELFIA® bedding by mesasuring all the adverse events likend to its use.
Following the withdrawal from the market of the first version of the SECURIDRAP® SELFIA®, this clinical investigation is being carried out at the request and on the recommandation of the ASNM in order to assess the safety of the second version of the SECURIDRAP® SELFIA® coating.
The proposed study is a prospective, multicenter, interventional and non-comparative research.
This clinical investigation is carried out in real life in accordance with the usual care for all patient with a prescription for SECURIDRAP® SELFIA® and who meet the eligibility criteria, in nursing homes and public and private hospitals based in France.
This interventional clinical investigation with minimal risks and constraints aims to confirm the safety of use of SECURIDRAP® SELFIA® in healthcare establishment.
The patient will be followed for 15 nigths, during witch an independent assessor will ensure that the conditions of use os the SECURIDRAP® SELFIA® sleeping bag are respected.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SECURIDRAP® SELFIA® | Other | Use of a SECURIDRAP® SELFIA® restraint system Monitoring with passage of an independent assessor |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SECURIDRAP® SELFIA® | Other | Use of SECURIDRAP® SELFIA® for 15 night |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of occurrence of adverse events related to the use of SÉCURIDRAP® SELFIA® | quotient of the number of overnight stays or at least one adverse event related to the use of SÉCURIDRAP® SELFIA® appeared, by the number of overnight stays where SÉCURIDRAP® SELFIA® was used | [15 days] |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of occurrence of user errors that could endanger patient safety | These usage errors will be measured during the verification of correct use of the SÉCURIDRAP® SELFIA® by the independent assessor, 2 hours after patient has been installed in the medical device | [15 days] |
| Rate of patients remaining bedridden each night for the duration of the sudy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Céline BETOUX | Contact | 0241637810 | c.betoux@mulliez-flory.fr | |
| Kelly LAVERGNE | Contact | 0231932118 | kelly.lavergne@evamed.fr |
| Name | Affiliation | Role |
|---|---|---|
| François Pr PUISIEUX | CHU Lille | Principal Investigator |
| Aline Dr CORVOL | Rennes University Hospital | Principal Investigator |
| Sabine Dr AHMINE |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CMMF de Bailleul | Recruiting | Bailleul | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003221 | Confusion |
| D060825 | Cognitive Dysfunction |
| D001523 | Mental Disorders |
| ID | Term |
|---|---|
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
non-comparative clinical investigation
Not provided
Not provided
Not provided
Not provided
P = [(NNL)/ (NU)] x 100 with:
|
| [15 days] |
| Satisfaction rate of healthcare teams using SÉCURIDRAP® SELFIA®, in terms of time savings, weel-being, comfort and respect for the dignity of patient | Time saving for healthcare teams via a graduated scale of 0-10 The weel-being / comfort of the patient via a graduated scale of 0-10 Respect for the dignity of the patient via a graduated scale of 0-10 | [15 days] |
| The learning curve for using SECURIDRAP® SELFIA® by healthcare team | The curve reflects the time required for nursing expertise in the use of SECURIDRAP. | [15 days] |
| Hospices Civils de Lyon |
| Principal Investigator |
| Thierry Dr LECRIQUE | CSSR La Clauze | Principal Investigator |
| Brigitte Dr GERS | USSAP- ASM LIMOUX | Principal Investigator |
| Marguerite Dr REY | USSAP- ASM LIMOUX | Principal Investigator |
| Valérie Dr WIEL | EHPAD l'Aquarelle | Principal Investigator |
| Brigitte Dr TILMONT | CMMF de Bailleul | Principal Investigator |
| Eddy Dr BAHEU | CH Hazebrouck | Principal Investigator |
| Denis Dr LEFEBVRE | CH Le Quesnoy | Principal Investigator |
| Philippe Dr VEAU | CSSR La Clauze | Principal Investigator |
| Pearlide Dr Kizonzolo-de-Bello | CHG Roubaix | Principal Investigator |
| EHPAD l'Aquarelle | Recruiting | Bully-les-Mines | France |
|
| Centre Hospitalier d'Hazebrouck | Recruiting | Hazebrouck | France |
|
| Centre Hospitalier Le Quesnoy | Recruiting | Le Quesnoy | France |
|
| CHU Lille | Recruiting | Lille | France |
|
| Ussap- Asm Limoux | Recruiting | Limoux | France |
|
| CHU Lyon | Recruiting | Lyon | France |
|
| CHU Rennes | Recruiting | Rennes | France |
|
| CHG Roubaix | Recruiting | Roubaix | France |
|
| CSSR La Clauze | Recruiting | Saint-Jean-Delnous | France |
|
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |